Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Jan Marsal, Manuel Barreiro–de Acosta, Irina Blumenstein, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 46

Showing 1-25 of 46 citing articles:

Enhancing Regulatory T Cells to Treat Inflammatory and Autoimmune Diseases
Tara Fiyouzi, Hector F. Pelaez-Prestel, Raquel Ruz Reyes, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 7797-7797
Open Access | Times Cited: 27
A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis
Marek Vébr, Renata Pomahačová, Josef Sýkora, et al.
Biomedicines (2023) Vol. 11, Iss. 12, pp. 3229-3229
Open Access | Times Cited: 23
Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
Mathurin Fuméry, Mélanie Serrero, Guillaume Bouguen, et al.
Journal of Crohn s and Colitis (2024) Vol. 18, Iss. 10, pp. 1615-1621
Closed Access | Times Cited: 5
Small Molecules in the Treatment of Acute Severe Ulcerative Colitis: A Review of Current Evidence
Raffaele Pellegrino, Giuseppe Imperio, Ilaria De Costanzo, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 308-308
Open Access
VCAM-1 as a common biomarker in inflammatory bowel disease and colorectal cancer: unveiling the dual anti-inflammatory and anti-cancer capacities of anti-VCAM-1 therapies
Jessica R. Pickett, Yuao Wu, Hang T. Ta
Cancer and Metastasis Reviews (2025) Vol. 44, Iss. 2
Open Access
The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study
Ammena Y. Binsaleh, Sahar M. El-Haggar, Sahar K. Hegazy, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Current Evidence for Combined Targeted Therapy for the Treatment of Inflammatory Bowel Disease
Panu Wetwittayakhlang, Péter L. Lakatos
Journal of the Canadian Association of Gastroenterology (2023) Vol. 7, Iss. 1, pp. 22-29
Open Access | Times Cited: 12
Safety and Monitoring of Inflammatory Bowel Disease Advanced Therapies
Shubha Bhat, Benjamin Click, Miguel Regueiro
Inflammatory Bowel Diseases (2023) Vol. 30, Iss. 5, pp. 829-843
Closed Access | Times Cited: 10
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials
Panu Wetwittayakhlang, Talat Bessissow, Péter L. Lakatos
Expert Opinion on Emerging Drugs (2024) Vol. 29, Iss. 1, pp. 19-34
Closed Access | Times Cited: 3
Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis
Evi Zhuleku, Daniel Wirth, R Nissinen, et al.
Therapeutic Advances in Gastroenterology (2024) Vol. 17
Open Access | Times Cited: 3
Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review
Liang‐Fang Wang, Pingrun Chen, Si-Ke He, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 29, pp. 4481-4498
Open Access | Times Cited: 9
A practical guide to combination advanced therapy in inflammatory bowel disease
Christina M. Ray, Remo Panaccione, Christopher Ma
Current Opinion in Gastroenterology (2024) Vol. 40, Iss. 4, pp. 251-257
Closed Access | Times Cited: 2
Approach to loss of response to advanced therapies in inflammatory bowel disease
Nikil Vootukuru, Abhinav Vasudevan
World Journal of Gastroenterology (2024) Vol. 30, Iss. 22, pp. 2902-2919
Open Access | Times Cited: 2
Establishment of a 96-well transwell system using primary human gut organoids to capture multiple quantitative pathway readouts
Charles Wright, Naomi Li, Lynsey Shaffer, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 7
An international multicentre study of SwiTching from Intravenous to subcutaneous inflixiMab and vEdolizumab in inflammatory bowel diseases: The TIME study
Ferdinando D’Amico, Luca Massimino, Giulia Palmieri, et al.
European Journal of Clinical Investigation (2024) Vol. 54, Iss. 11
Open Access | Times Cited: 2
Efficacy of Second-Line Biological Therapies in Moderate to Severe Ulcerative Colitis Patients with Prior Failure of Anti-Tumor Necrosis Factor Therapy: A Multi-Center Study
Ji-Eun Na, Yong-Eun Park, Jongha Park, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 10, pp. 1066-1066
Open Access | Times Cited: 2
Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations
Ole Haagen Nielsen, Alexander Hammerhøj, Mark Ainsworth, et al.
Drugs (2024)
Closed Access | Times Cited: 2
Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review
Zachary Green, R. Mark Beattie, James J. Ashton
Translational Pediatrics (2023) Vol. 12, Iss. 10, pp. 1853-1874
Open Access | Times Cited: 6
Discovering the Nutrition-Microbiota Interplay in Inflammatory Bowel Disease: Are We There Yet?
Marilina Florio, Lucilla Crudele, Antonio Moschetta, et al.
Endocrinology (2024), pp. 333-371
Closed Access | Times Cited: 1
An in vitro study elucidating the synergistic effects of aqueous cinnamon extract and an anti-TNF-α biotherapeutic: implications for a complementary and alternative therapy for non-responders
Shubrata Khedkar, Minhaj Ahmad Khan
BMC Complementary Medicine and Therapies (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept study
Kenji Suzuki, Yukinori Sameshima, Junji Yokoyama, et al.
Inflammation and Regeneration (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 1
Exploring the potential of human intestinal organoids: Applications, challenges, and future directions
Inês A. Parente, Linda Chiara, Simona Bertoni
Life Sciences (2024) Vol. 352, pp. 122875-122875
Open Access | Times Cited: 1
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn’s Disease in the SERENE Studies
Bram Verstockt, Valerie Pivorunas, Naim Al Mahi, et al.
Journal of Crohn s and Colitis (2023) Vol. 18, Iss. 4, pp. 493-505
Open Access | Times Cited: 4
المراقبة الدوائية العلاجية للإنفلاكسيماب في المرضى العراقيين المصابين بمرض كرون
Hussein Hazim Saleh, Dheyaa Jabbar Khadim, Raghad Jawad Hussein
Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ) (2024) Vol. 6, Iss. 1, pp. 239-245
Closed Access | Times Cited: 1
From animal models to gut-on-chip: the challenging journey to capture inter-individual variability in chronic digestive disorders
Aïcha Kriaa, Vincent Mariaule, Charlotte De Rudder, et al.
Gut Microbes (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top